| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Evommune Inc. | EVO301 | Ulcerative Colitis | Phase 2 | Trial Planned | Intravenous | Gastroenterology |
| Evommune Inc. | EVO756 | Atopic Dermatitis | Phase 2b | Ongoing | Inhalation | Immunology |
| Evommune Inc. | EVO756 | Chronic Spontaneous Urticaria | Phase 2b | Ongoing | Inhalation | Immunology |
| Evommune Inc. | EVO301 | Atopic Dermatitis | Phase 2a | Ongoing | Intravenous | Immunology |
| Evotec SE | BAY 3401016 - (ASSESS) | Alport Syndrome | Phase 2a | Enrollment Initiation | oral | Genetic Disorder |
| Exelixis Inc. | Cabozantinib w/ pembrolizumab | Recurrent or metastatic head and neck cancer | Phase 2 | Trial Completed | Oral with intravenous | Oncology |
| Exelixis Inc. | Zanzalintinib - (STELLAR-304) | Advanced non-clear cell renal cell carcinoma (nccRCC) | Phase 3 | Ongoing | Oral | Oncology |
| Exelixis Inc. | Zanzalintinib - (STELLAR-304) | Advanced non-clear cell renal cell carcinoma (nccRCC) | Phase 3 | Ongoing | Oral | Oncology |